The blood platelet proteome is changed in UREMIC patients

Walkowiak, Bogdan; Kamińska, M.; Okrój, W.; Tański, Wojciech; Sobol, Anna; Zbróg, Zbigniew; Przybyszewska-Doros, Iwona

doi:10.1080/09537100601095871

Cited by 16 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previously reported alteration of the protein expression profile in circulating platelets of CKD patients (21,22) prompted us to examine the impact of CKD on the platelet mRNA transcriptome. Microarray profiling of platelet mRNAs on pooled RNA samples revealed that the majority of platelet mRNAs is not markedly affected in uremic and dialysis patients, as compared to control healthy subjects.…”

Section: Differential Platelet Mrna Profile Of Uremic and Dialysis Pamentioning

confidence: 99%

“…Proteomic analyses of platelets revealed that their protein expression profile is altered in CKD patients (21,22). Although reticulated platelets sustain changes in terms of platelet volume, morphology and RNA content in subjects treated with hemodialysis (23,24), whether the mRNA profile of platelets is altered in CKD and hemodialysis patients remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Alteration of the platelet transcriptome in chronic kidney disease

Plé

Maltais²,

Corduan³

et al. 2012

Thromb Haemost

View full text Add to dashboard Cite

Bleeding and thrombotic disorders are major complications affecting patients with chronic kidney disease (CKD). Exposure of circulating platelets to uraemic toxins and contact with artificial surfaces during dialysis induce platelet abnormalities and alter the platelet proteome. We hypothesised that these changes may be subsequent to changes in the composition and/or regulation of the platelet transcriptome. In this study, we investigated the circulating platelets of 10 CKD patients (i.e. five chronic haemodialysis patients and five stage 4 CKD uraemic patients) and five age- and sex-matched healthy subjects. We observed an alteration of the platelet messenger RNA (mRNA) and microRNA transcriptome in CKD patients. Impaired in uraemic platelets, the levels of some mRNAs and of most microRNAs appeared to be corrected by dialysis, which is consistent with a beneficial effect of dialysis and a mRNA regulatory role of platelet microRNAs. Reduced in platelets of uraemic patients, phosphatidylcholine transfer protein (PCTP) and WD repeat-containing protein 1 (WDR1) were found to be regulated by microRNAs, the latter of which involving hsa-miR-19b, a microRNA increased in platelets of uraemic patients and involved in platelet reactivity. These results suggest that an alteration of microRNA-based mRNA regulatory mechanisms may underlie the platelet response to uremia and entail the development of platelet-related complications in CKD.

show abstract

Section: Differential Platelet Mrna Profile Of Uremic and Dialysis Pamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Alteration of the platelet transcriptome in chronic kidney disease

Plé

Maltais²,

Corduan³

et al. 2012

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…The first proteomic evaluation performed in uremic platelets was carried out by Walkowiak et al [70]. In this preliminary work, the authors performed a comparative analysis using 2DE (IPG strips pH 3-10, 11 cm and Excel gels 12.5) to separate the platelet proteins of uremic patients, both dialyzed (n=9) and non dialyzed (n=9), and healthy controls (n=9).…”

Section: Platelet Cellmentioning

confidence: 99%

Blood Cell Proteomics in Chronic Kidney Disease

Bonomini¹,

Pieroni²,

Ronci³

et al. 2018

TOUNJ

View full text Add to dashboard Cite

Background: The uremic syndrome mimes a systemic poisoning with the retention of numerous compounds which are normally removed by the kidney. The study of proteins and peptides, or proteomics, represents an important field of research for the investigation of blood and blood diseases. Methods and Materials: We focused our review on the results of proteomic investigations on blood cells of uremic patients with particular regard to the study of red blood cells, platelets, and monocytes. Results: In literature there are few, preliminary studies on platelets and monocytes while the knowledge on uremic erythrocytes is much wider. Proteomic investigations showed that erythrocyte membrane proteome of uremic patients, differs significantly from the proteome of healthy subjects, being characterized by an extensive remodeling which may influence visco-elastic properties of RBC such as deformability and involve diverse molecular pathways driving red blood cell signaling and removal. Conclusion: Proteomic technologies emerged as a useful tool in defining and characterizing both physiological and disease processes being able, among others, to give important insights into uremic anemia.

show abstract

“…Platelets and platelet granules were studied in patients with gray platelet syndrome [27,28], Quebec platelet disorder [29], and ␦-storage pool disease [30]. Other diseases investigated by platelet proteomics were: hypertension [31], arterial thrombosis [32], uremia [33,34], cystic fibrosis [35], neurodegenerative diseases [36,37], myelodysplastic syndromes [38], and thalassemia [39]. All the above studies provided biochemical evidences on the role of platelets in various diseases; a summary of main results is shown in Table 1.…”

Section: Maldi-tof/tofmentioning

confidence: 99%

Platelet clinical proteomics: Facts, challenges, and future perspectives

García

2016

Proteomics Clinical Apps

View full text Add to dashboard Cite

In recent years, proteomics has been applied to platelet clinical research. Platelets are small enucleated cells that play a fundamental role in hemostasis. In a pathological context, unwanted platelet activation is related to various diseases, primarily thrombosis, but also cancer metastasis, inflammation, immunity, and neurodegenerative diseases. The absence of a nucleus is one of the reasons why proteomics can be considered an ideal analytical tool for platelet research. Indeed, platelet proteomics has allowed the identification of many novel signaling proteins and receptors, several of which are being pursued as potential therapeutic targets. Encouraged by this success, several research groups have recently initiated clinical proteomics studies covering diseases where platelets are involved in some way, such as coronary artery disease, storage pool diseases, uremia, cystic fibrosis, and Alzheimer disease. The goal was to identify platelet biomarkers and drug targets that can help to improve the treatment/diagnosis of the disease and provide further mechanistic evidences of the role platelets play in the pathology. The present article will comment on the recent progress of clinical proteomics in the context of platelet research, challenges, and perspectives for the future ahead.

show abstract

The blood platelet proteome is changed in UREMIC patients

Cited by 16 publications

References 8 publications

Alteration of the platelet transcriptome in chronic kidney disease

Alteration of the platelet transcriptome in chronic kidney disease

Blood Cell Proteomics in Chronic Kidney Disease

Platelet clinical proteomics: Facts, challenges, and future perspectives

Contact Info

Product

Resources

About